# The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee

> **NCT02464501** · NA · COMPLETED · sponsor: **Horizons International Peripheral Group** · enrollment: 112 (actual)

## Conditions studied

- Peripheral Arterial Disease
- Cardiovascular Disease
- Peripheral Vascular Disease

## Interventions

- **OTHER:** Paclitaxel administration using the OPC

## Key facts

- **NCT ID:** NCT02464501
- **Lead sponsor:** Horizons International Peripheral Group
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-20
- **Primary completion:** 2019-09
- **Final completion:** 2019-11
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2019-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02464501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02464501, "The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02464501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*